tbuckley/cabot-search huggingface dataset:
Amelioration of ligamentum flavum hypertrophy using umbilical cord mesenchymal stromal cell-derived extracellular vesicles
Authors: Cheng Ma, Xin Qi, Yi-Fan Wei, Zhi Li, He-Long Zhang, He Li, Feng-Lei Yu, Ya-Nan Pu, Yong-Can Huang, Yong-Xin Ren
Journal: Bioactive Materials (2022)

Ligamentum flavum (LF) hypertrophy (LFH) has been recognised as one of the key contributors to lumbar spinal stenosis. Currently, no effective methods are available to ameliorate this hypertrophy. In this study, human umbilical cord mesenchymal stromal cell-derived extracellular vesicles (hUCMSC-EVs) were introduced for the first time as promising vehicles for drug delivery to treat LFH. The downregulation of miR-146a-5p and miR-221-3p expressions in human LF tissues negatively correlated with increased LF thickness. The hUCMSC-EVs enriched with these two miRNAs significantly suppressed LFH in vivo and notably ameliorated the progression of transforming growth factor β1(TGF-β1)-induced fibrosis in vitro after delivering these two miRNAs to mouse LF cells. The results further demonstrated that miR-146a-5p and miR-221-3p directly bonded to the 3'-UTR regions of SMAD4 mRNA, thereby inhibiting the TGF-β/SMAD4 signalling pathway. Therefore, this translational study determined the effectiveness of a hUCMSC-EVs-based approach for the treatment of LFH and revealed the critical target of miR-146a-5p and miR-221-3p. Our findings provide new insights into promising therapeutics using a hUCMSC-EVs-based delivery system for patients with lumbar spinal stenosis.
High prevalence of multiple serotypes of pneumococci in patients with pneumonia and their associated risk factors
Authors: Bhim Gopal Dhoubhadel, Motoi Suzuki, Tomoko Ishifuji, Makito Yaegashi, Norichika Asoh, Masayuki Ishida, Sugihiro Hamaguchi, Masahiro Aoshima, Michio Yasunami, Koya Ariyoshi, Konosuke Morimoto
Journal: Thorax (2022)

Background Multiple serotypes of pneumococci have epidemiological and clinical implications, such as the emergence of non-vaccine serotypes and the acquisition of antimicrobial resistance. Prevalence of multiple serotypes of pneumococci in adults and their risk factors are not known. Methods We enrolled adult patients from age ≥15 years with radiologically confirmed pneumonia in four hospitals across Japan. Pneumococcal pneumonia was defined with a pneumococcal bacterial density of ≥10 4 /mL in sputum by lytA quantitative PCR, and serotypes were determined. Pneumonias with a single serotype were categorised as single-serotype pneumococcal pneumonia and with two or more serotypes as multiple-serotype pneumococcal pneumonia. Multivariable logistic regression was used to assess the risk factors. Results 3470 patients (median age 77 years, IQR 65–85) were enrolled. Pneumococcal pneumonia was identified in 476 (18.3%, n=2605) patients. Multiple serotypes were detected in 42% of them. Risk of having multiple serotypes was low among patients who had received 23-valent pneumococcal polysaccharide vaccine (PPSV23) vaccines (adjusted OR 0.51 (95% CI 0.27 to 0.94)). Proportion of non-PCV7 PPSV23 serotypes in overall distribution of multiple serotypes was 67.4% (n=324/481) compared with 46.4% (n=128/276) in that of single serotypes (p=0.001). Serotypes 5, 9N/9L, 10A, 12/22/46, 17F and 35F were associated with multiple-serotype pneumonia, and serotypes 6A/6B, 23F, 11 and 6C/6D were associated with single-serotype pneumonia. Proportion of more invasive serotypes (serotypes 1, 5, 7F, 8) was significantly higher in multiple-serotype pneumonia (p=0.001). Conclusions Multiple serotypes of pneumococci are common in sputum of adult patients with pneumonia. The risk of multiple-serotype pneumococcal pneumonia is lower than that of single-serotype pneumococcal pneumonia among PPSV23-vaccinated patients. Trial registration number UMIN000006909.
Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study
Authors: Mar Riveiro-Barciela, Ana Barreira-Díaz, Ana Callejo-Pérez, Eva Muñoz-Couselo, Nely Díaz-Mejía, Álvaro Díaz-González, María-Carlota Londoño, Maria-Teresa Salcedo, María Buti
Journal: Clinical Gastroenterology and Hepatology (2022)
Correction to: Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals
Authors: Fabrizio Schifano, Valeria Catalani, Safia Sharif, Flavia Napoletano, John Martin Corkery, Davide Arillotta, Suzanne Fergus, Alessandro Vento, Amira Guirguis
Journal: Drugs (2022)
The Need for a Global Approach to the Ethical Evaluation of Healthcare Machine Learning
Authors: Tijs Vandemeulebroucke, Yvonne Denier, Chris Gastmans
Journal: The American Journal of Bioethics (2022)

This article is referred to by:Promoting Ethical Deployment of Artificial Intelligence and Machine Learning in HealthcareResponse to Open Peer Commentaries: On Social Harms, Big Tech, and Institutional Accountability
Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition
Authors: Justin T. Low, Vidyalakshmi Chandramohan, Michelle L. Bowie, Michael C. Brown, Matthew S. Waitkus, Aaron Briley, Kevin Stevenson, Rebecca Fuller, Zachary J. Reitman, Andrea M. Muscat, Seethalakshmi Hariharan, Janell Hostettler, Sarah Danehower, Ali Baker, Mustafa Khasraw, Nicholas C. Wong, Simon Gregory, Smita K. Nair, Amy Heimberger, Matthias Gromeier, Darell D. Bigner, David M. Ashley
Journal: Cancer Cell (2022)
Who Is at Risk for Heart Failure?
Authors: Clyde W. Yancy, Sadiya S. Khan
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Authors: Smita S. Chandran, Jiaqi Ma, Martin G. Klatt, Friederike Dündar, Chaitanya Bandlamudi, Pedram Razavi, Hannah Y. Wen, Britta Weigelt, Paul Zumbo, Si Ning Fu, Lauren B. Banks, Fei Yi, Enric Vercher, Inaki Etxeberria, Watchain D. Bestman, Arnaud Da Cruz Paula, Ilinca S. Aricescu, Alexander Drilon, Doron Betel, David A. Scheinberg, Brian M. Baker, Christopher A. Klebanoff
Journal: Nature Medicine (2022)

Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes derived from recurrently mutated driver genes. Here we describe a high-throughput platform combining single-cell transcriptomic and T cell receptor (TCR) sequencing to establish whether mutant PIK3CA, among the most frequently genomically altered driver oncogenes, generates an immunogenic public NeoAg. Using this strategy, we developed a panel of TCRs that recognize an endogenously processed neopeptide encompassing a common PIK3CA hotspot mutation restricted by the prevalent human leukocyte antigen (HLA)-A*03:01 allele. Mechanistically, immunogenicity to this public NeoAg arises from enhanced neopeptide/HLA complex stability caused by a preferred HLA anchor substitution. Structural studies indicated that the HLA-bound neopeptide presents a comparatively 'featureless' surface dominated by the peptide's backbone. To bind this epitope with high specificity and affinity, we discovered that a lead TCR clinical candidate engages the neopeptide through an extended interface facilitated by an unusually long CDR3β loop. In patients with diverse malignancies, we observed NeoAg clonal conservation and spontaneous immunogenicity to the neoepitope. Finally, adoptive transfer of TCR-engineered T cells led to tumor regression in vivo in mice bearing PIK3CA-mutant tumors but not wild-type PIK3CA tumors. Together, these findings establish the immunogenicity and therapeutic potential of a mutant PIK3CA-derived public NeoAg.
Risks of Comorbidities in Patients With Palmoplantar Pustulosis vs Patients With Psoriasis Vulgaris or Pompholyx in Korea
Authors: Dong Hyo Kim, Jin Yong Lee, Soo Ick Cho, Seong Jin Jo
Journal: JAMA Dermatology (2022)

Palmoplantar pustulosis (PPP) has been reported to be accompanied by systemic conditions. However, the risks of comorbidities in patients with PPP have rarely been evaluated.To assess the risks of comorbidities in patients with PPP compared with patients with psoriasis vulgaris or pompholyx.This nationwide population-based cross-sectional study used data from the Korean National Health Insurance database and the National Health Screening Program collected from January 1, 2010, to December 31, 2019. Data were analyzed from July 1, 2020, to October 31, 2021. Korean patients diagnosed with PPP, psoriasis vulgaris, or pompholyx who visited a dermatologist between January 1, 2010, and December 31, 2019, were enrolled.Presence of PPP.The risks of comorbidities among patients with PPP vs patients with psoriasis vulgaris or pompholyx were evaluated using a multivariable logistic regression model.A total of 37 399 patients with PPP (mean [SD] age, 48.98 [17.20] years; 51.7% female), 332 279 patients with psoriasis vulgaris (mean [SD] age, 47.29 [18.34] years; 58.7% male), and 365 415 patients with pompholyx (mean [SD] age, 40.92 [17.63] years; 57.4% female) were included in the analyses. Compared with patients with pompholyx, those with PPP had significantly higher risks of developing psoriasis vulgaris (adjusted odds ratio [aOR], 72.96; 95% CI, 68.19-78.05; P < .001), psoriatic arthritis (aOR, 8.06; 95% CI, 6.55-9.92; P < .001), ankylosing spondylitis (aOR, 1.91; 95% CI, 1.61-2.27; P < .001), type 1 diabetes (aOR, 1.33; 95% CI, 1.16-1.52; P < .001), type 2 diabetes (aOR, 1.33; 95% CI, 1.29-1.38; P < .001), Graves disease (aOR, 1.25; 95% CI, 1.11-1.42; P < .001), Crohn disease (aOR, 1.63; 95% CI, 1.11-2.40; P = .01), and vitiligo (aOR, 1.87; 95% CI, 1.65-2.12; P < .001) after adjusting for demographic covariates. The risks of ankylosing spondylitis (aOR, 1.37; 95% CI, 1.16-1.62; P < .001) and Graves disease (aOR, 1.40; 95% CI, 1.23-1.58; P < .001) were significantly higher among patients with PPP vs psoriasis vulgaris. However, the risks of psoriatic arthritis (aOR, 0.54; 95% CI, 0.47-0.63; P < .001), systemic lupus erythematosus (aOR, 0.67; 95% CI, 0.46-0.97; P = .04), Sjögren syndrome (aOR, 0.70; 95% CI, 0.50-0.96; P = .03), systemic sclerosis (aOR, 0.29; 95% CI, 0.11-0.77; P = .01), vitiligo (aOR, 0.53; 95% CI, 0.47-0.60; P < .001), and alopecia areata (aOR, 0.88; 95% CI, 0.81-0.95; P = .001) were significantly lower among those with PPP vs psoriasis vulgaris.The results of this cross-sectional study suggest that patients with PPP have an overlapping comorbidity profile with patients with psoriasis vulgaris but not patients with pompholyx. However, the risks of comorbidities among patients with PPP may be substantially different from those among patients with psoriasis vulgaris.
Emerging Paradigms in Type 2 Immunity
Authors: Hamida Hammad, Nincy Debeuf, Helena Aegerter, Andrew S. Brown, Bart N. Lambrecht
Journal: Annual Review of Immunology (2022)

A principal purpose of type 2 immunity was thought to be defense against large parasites, but it also functions in the restoration of homeostasis, such as toxin clearance following snake bites. In other cases, like allergy, the type 2 T helper (Th2) cytokines and cells present in the environment are detrimental and cause diseases. In recent years, the recognition of cell heterogeneity within Th2-associated cell populations has revealed specific functions of cells with a particular phenotype or gene signature. In addition, here we discuss the recent data regarding heterogeneity of type 2 immunity–related cells, as well as their newly identified role in a variety of processes ranging from involvement in respiratory viral infections [especially in the context of the recent COVID-19 (coronavirus disease 2019) pandemic] to control of cancer development or of metabolic homeostasis.
Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL
Authors: Christian Labenz, Anita Arslanow, Marc Nguyen-Tat, Michael Nagel, Marcus-Alexander Wörns, Matthias Christian Reichert, Franz Josef Heil, Dagmar Mainz, Gundula Zimper, Barbara Römer, Harald Binder, Erik Farin-Glattacker, Urs Fichtner, Erika Graf, Dominikus Stelzer, Reyn Van Ewijk, Julia Ortner, Louis Velthuis, Frank Lammert, Peter R. Galle
Journal: Journal of Hepatology (2022)
Decoupling the role of chemistry and microstructure in hMSCs response to an osteoinductive calcium phosphate ceramic
Authors: V.P. Galván-Chacón, D. de Melo Pereira, S. Vermeulen, H. Yuan, J. Li, P. Habibović
Journal: Bioactive Materials (2022)

Calcium phosphates (CaP) are widely used synthetic bone graft substitutes, having bioactivity that is regulated by a set of intertwined physico-chemical and structural properties. While some CaPs have shown to be as effective in regenerating large bone defects as autologous bone, there is still the need to understand the role of individual material properties in CaP performance. Here, we aimed to decouple the effects of chemical composition and surface-microstructure of a beta-tricalcium phosphate (TCP) ceramic, with proven osteoinductive potential, on human mesenchymal stromal cells (hMSCs) differentiation. To this end, we replicated the surface structure of the TCP ceramic into polylactic acid without inorganic additives, or containing the chemical constituents of the ceramic, i.e., a calcium salt, a phosphate salt, or TCP powder. The microstructure of the different materials was characterized by confocal laser profilometry. hMSCs were cultured on the materials, and the expression of a set of osteogenic genes was determined. The cell culture medium was collected and the levels of calcium and phosphate ions were quantified by inductively-coupled plasma mass spectrometry. The results revealed that none of the tested combinations of properties in polymer/composite replicas was as potent in supporting the osteogenic differentiation of hMSCs as the original ceramic. Nevertheless, we observed some effects of the surface structure in the absence of inorganics, as well as combined effects of surface structure and the added salts, in particular calcium, on osteogenic differentiation. The approach presented here can be used to study the role of independent properties in other CaP-based biomaterials.
Sustained endosomal release of a neurokinin-1 receptor antagonist from nanostars provides long-lasting relief of chronic pain
Authors: Rocco Latorre, Paulina D. Ramírez-Garcia, Alan Hegron, James L. Grace, Jeffri S. Retamal, Priyank Shenoy, Mai Tran, Luigi Aurelio, Bernard Flynn, Daniel P. Poole, Rafael Klein-Cloud, Dane D. Jensen, Thomas P. Davis, Brian L. Schmidt, John F. Quinn, Michael R. Whittaker, Nicholas A. Veldhuis, Nigel W. Bunnett
Journal: Biomaterials (2022)
Suicide Deaths Among Women in California Living With Handgun Owners vs Those Living With Other Adults in Handgun-Free Homes, 2004-2016
Authors: Matthew Miller, Yifan Zhang, Lea Prince, Sonja A. Swanson, Garen J. Wintemute, Erin E. Holsinger, David M. Studdert
Journal: JAMA Psychiatry (2022)

Little is known about the extent to which secondhand exposure to household firearms is associated with risk of suicide in adults who do not own guns, most of whom are women.
Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies
Authors: Mazdak M. Bradberry, Natalie Gukasyan, Charles L. Raison
Journal: JAMA Psychiatry (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Impact of low-molecular-weight heparin in the treatment of moderately severe and severe acute pancreatitis; a randomized, single blind, phase 3 control trial
Authors: Basavaraj Patil, Laxmi Narayan Meena, Dinesh Chandra Sharma, Garima Agarwal, Yogendra Dadhich, Gaurav Gupta
Journal: International Journal of Surgery (2022)
Au@MnSe<sub>2</sub> Core–Shell Nanoagent Enabling Immediate Generation of Hydroxyl Radicals and Simultaneous Glutathione Deletion Free of Pre‐Reaction for Chemodynamic‐Photothermo‐Photocatalytic Therapy with Significant Immune Response
Authors: Yuanlin Wang, Xiang Sun, Yaqian Han, Kai Wang, Lixin Cheng, Ye Sun, Flemming Besenbacher, Miao Yu
Journal: Advanced Healthcare Materials (2022)

As a typical tumor microenvironment-responsive therapy, chemodynamic therapy (CDT), producing hydroxyl radicals (• OH) to eliminate tumor cells, has demonstrated great promise. Nevertheless, there are still major challenges: • OH generated from endogenous H2 O2 is usually insufficient; the CDT effect is strongly dependent on the pre-reaction with glutathione. Addressing the challenges, Au@MnSe2 core-shell nanoagent for synergetic chemodynamic-photothermo-photocatalytic therapy combined with tetramodal imaging, including magnetic resonance imaging, computed tomography, photoacoustic, and infrared thermal imaging is reported. Distinct from the reported glutathione-depleting agents, Mn2+ in MnSe2 allows immediate generation of • OH, independent of pre-reaction. Meanwhile, Mn3+ consumes glutathione by its conversion to Mn2+ . The Au-MnSe2 combination promotes photothermal conversion and photocatalytic reaction, resulting in largely enhanced • OH generation from endogenous H2 O2 and significant hyperthermia. Meanwhile, immune response is effectively activated: the intratumoral expression of programmed cell death-1 and proinflammatory cytokines increase to 4-7 folds; the cytotoxic and helper T lymphocytes cells in the tumor area increase to more than 2.5-folds; an evident, temporary systemic immunostimulatory effect is demonstrated. High tumor inhibition rate (≈97.3%) and greatly prolonged survival are obtained. This highly-integrated design coordinating three different therapies with four different imaging modals provide new possibilities for high-performance theranostic nanoagents.
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis
Authors: Shima Ahmady, Maud H. E. Jansen, Patty J. Nelemans, Janneke P. H. M. Kessels, Aimee H. M. M. Arits, Michette J. M. de Rooij, Brigitte A. B. Essers, Patricia J. F. Quaedvlieg, Nicole W. J. Kelleners-Smeets, Klara Mosterd
Journal: JAMA Dermatology (2022)

Treatment of actinic keratosis (AK) aims to prevent cutaneous squamous cell carcinoma (cSCC). However, whether AK can progress into invasive cSCC is a matter of debate, and little is known about the effect of treatment on preventing cSCC.To evaluate the risk of invasive cSCC and factors that may contribute to increased risk in patients with multiple AKs.In this secondary analysis of a multicenter randomized clinical trial, 624 patients with a minimum of 5 AKs within an area of 25 to 100 cm2 on the head were recruited from the Department of Dermatology of 4 hospitals in the Netherlands. Long-term follow-up was performed from July 1, 2019, to December 31, 2020.Patients were randomized to treatment with 5% fluorouracil, 5% imiquimod cream, methylaminolevulinate photodynamic therapy, or 0.015% ingenol mebutate gel.The primary outcome was the proportion of patients with invasive cSCC in the target area during follow-up. Secondary outcomes were the associations between risk of invasive cSCC and a priori defined potential prognostic factors, including type of treatment, severity of AK (Olsen grade), history of nonmelanoma skin cancer, and additional treatment.Of the 624 patients (558 [89.4%] male; median age, 73 years [range, 48-94 years]) in the study, 26 were diagnosed with a histologically proven invasive cSCC in the target area during follow-up. The total 4-year risk of developing cSCC in a previously treated area of AK was 3.7% (95% CI, 2.4%-5.7%), varying from 2.2% (95% CI, 0.7%-6.6%) in patients treated with fluorouracil to 5.8% (95% CI, 2.9%-11.3%) in patients treated with imiquimod. In patients with severe AK (Olsen grade III), the risk was 20.9% (95% CI, 10.8%-38.1%), and the risk was especially high (33.5%; 95% CI, 18.2%-56.3%) in patients with severe AK who needed additional treatment.In this secondary analysis of a randomized clinical trial, risk of invasive cSCC was highest in patients with Olsen grade III AK and was substantially increased in patients who received additional treatment. These patients should be closely followed up after treatment.ClinicalTrials.gov Identifier: NCT02281682.
Efficacy of Therapies for Actinic Keratosis—Reply
Authors: Markus V. Heppt, Theresa Steeb, Carola Berking
Journal: JAMA Dermatology (2022)

In Reply Thank you for the opportunity to reply to the comments raised Lim et al. We appreciate their interest in our research and cherish the constructive discussion on methodological limitations and the clinical relevance of the outcome selection in our study.1
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial
Authors: Roy Fleischmann, Alan Friedman, Edit Drescher, Atul Singhal, Gregorio Cortes-Maisonet, Thao Doan, Wenjing Lu, Zailong Wang, Ahmed Nader, William Housley, Stanley Cohen, Peter C Taylor, Ricardo Blanco
Journal: The Lancet Rheumatology (2022)
Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study
Authors: Joleen M. Hubbard, Enikő R. Tőke, Roberto Moretto, Rondell P. Graham, Hagop Youssoufian, Orsolya Lőrincz, Levente Molnár, Zsolt Csiszovszki, Jessica L. Mitchell, Jaclynn Wessling, József Tóth, Chiara Cremolini
Journal: Clinical Cancer Research (2022)

Although chemotherapy is standard of care for metastatic colorectal cancer (mCRC), immunotherapy has no role in microsatellite stable (MSS) mCRC, a "cold" tumor. PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from 7 tumor-associated antigens (TAA) frequently expressed in mCRC. This study assessed PolyPEPI1018 combined with first-line maintenance therapy in patients with MSS mCRC.